BioNTech SE : Vaccine revenue and strong balance sheet fund R&D in oncology. Potential tailwinds from ASCO
>Earnings estimates and target price lowered after the update on vaccine revenue estimates - We have adjusted our earnings model and the target price to our current expectations regarding COVID vaccine sales for the coming years. While it appears that a certain amount of base revenue will be achieved in the foreseeable future, especially with more vulnerable populations, our initial assumptions have proven overly optimistic. We have therefore revised down our forecast...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.